Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

TCR (T Cell Receptor) for recognizing PRAME (Preferentially Expressed Antigen of Melanoma) antigen oligopeptide

A variable, beta chain technology, applied in the field of TCR, can solve problems such as normal cell damage

Active Publication Date: 2019-03-01
XLIFESC LTD
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For the treatment of the above diseases, methods such as chemotherapy and radiotherapy can be used, but all of them will cause damage to their own normal cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • TCR (T Cell Receptor) for recognizing PRAME (Preferentially Expressed Antigen of Melanoma) antigen oligopeptide
  • TCR (T Cell Receptor) for recognizing PRAME (Preferentially Expressed Antigen of Melanoma) antigen oligopeptide
  • TCR (T Cell Receptor) for recognizing PRAME (Preferentially Expressed Antigen of Melanoma) antigen oligopeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0145] Example 1 Cloning of PRAME Antigen Short Peptide-Specific T Cells

[0146] Peripheral blood lymphocytes (PBL) from healthy volunteers with genotype HLA-A0201 were stimulated with the synthetic short peptide AVLDGLDVLL (SEQ ID NO.9; Beijing Saibaisheng Gene Technology Co., Ltd.). The AVLDGLDVLL short peptide was annealed with biotin-labeled HLA-A0201 to prepare pHLA haploids. These haploids were combined with PE-labeled streptavidin (BD Company) to form PE-labeled tetramers, and the tetramers and anti-CD8-APC double-positive cells were sorted. Sorted cells were expanded and subjected to secondary sorting as described above, followed by monoclonalization by limiting dilution. Monoclonal cells were stained with tetramers, and double-positive clones were screened. The screened double-positive clones were as follows: Figure 15 shown.

[0147] The function and specificity of the screened T cell clones were further detected by ELISPOT assay. Those skilled in the art are f...

Embodiment 2

[0151] Example 2 Obtaining the construction of TCR gene and carrier of PRAME antigen short peptide-specific T cell clone

[0152] with Quick-RNA TM MiniPrep (ZYMO research) extracted the total RNA of the antigenic short peptide AVLDGLDVLL-specific and HLA-A0201-restricted T cell clones screened in Example 1. The cDNA was synthesized using clontech's SMART RACE cDNA amplification kit, and the primers used were designed at the C-terminal conserved region of the human TCR gene. The sequence was cloned into T vector (TAKARA) for sequencing. It should be noted that this sequence is complementary and does not contain introns. After sequencing, the sequence structures of the TCR α chain and β chain expressed by the double-positive clone are shown in Figure 1 and Figure 2, respectively. Figure 1a , Figure 1b , Figure 1c , Figure 1d , Figure 1e and Figure 1f They are the amino acid sequence of TCRα chain variable domain, the nucleotide sequence of TCRα chain variable doma...

Embodiment 3

[0162] Example 3 Expression, refolding and purification of PRAME antigen short peptide-specific soluble TCR

[0163]In order to obtain a soluble TCR molecule, the α and β chains of the TCR molecule of the present invention may only include their variable domains and part of the constant domains respectively, and a cysteine ​​residue is introduced into the constant domains of the α and β chains respectively To form an artificial interchain disulfide bond, the positions of the introduced cysteine ​​residues are Thr48 of TRAC*01 exon 1 and Ser57 of TRBC2*01 exon 1; the amino acid sequence and nucleotides of the α chain sequence as Figure 3a and Figure 3b As shown, the amino acid sequence and nucleotide sequence of its β chain are as follows Figure 4a and Figure 4b The introduced cysteine ​​residues are shown in bold and underlined letters. The target gene sequences of the above TCRα and β chains were synthesized and inserted into the expression vector pET28a+ (Novagene )...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a TCR (T Cell Receptor) which is specifically combined with oligopeptide AVLDGLDVLL which derives PRAME (Preferentially Expressed Antigen of Melanoma) antigen, and the antigen oligopeptide AVLDGLDVLL and HLA A0201 form a compound and are represented to the surfaces of cells together. The invention further provides a nucleic acid molecule for encoding the TCR and a vector with the nucleic acid molecule. In addition, the invention further provides a cell for transducing the TCR provided by the invention.

Description

technical field [0001] The present invention relates to TCRs capable of recognizing short peptides derived from PRAME antigens. The present invention also relates to PRAME-specific T cells obtained by transducing the above TCRs, and their use in the prevention and treatment of PRAME-related diseases. Background technique [0002] PRAME is a preferentially expressed antigen of melanoma (PRAME), which is expressed in 88% of primary and 95% of metastatic melanoma (Ikeda H, etal. Immunity, 1997, 6(2): 199-208) , normal skin tissue and benign melanocytes are not expressed. After PRAME is produced in cells, it is degraded into small molecular polypeptides, and combines with MHC (major histocompatibility complex) molecules to form a complex, which is presented to the cell surface. AVLDGLDVLL is a short peptide derived from the PRAME antigen and is a target for the treatment of PRAME-associated diseases. In addition to melanoma, PRAME is also expressed in a variety of tumors, incl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/725C12N15/12C12N15/867C12N5/10A61K38/17A61P35/00A61P37/02
CPCA61K35/17A61K38/00C07K14/7051
Inventor 李懿相瑞瑞贾英吴显辉
Owner XLIFESC LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com